Sanofi & Regeneron's Dupixent receives US FDA approval to treat patients with bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). BP primarily affects elderly patients, and is characterized by intense itch, painful blisters, and lesions, as …